Pharmaceutical

Pharmaceutical clinical development depends on disciplined trial design, site execution, and data that hold up under regulatory review. Viltis supports sponsors and clinical teams running drug studies under ICH GCP, from early proof-of-concept through confirmatory Phase III and post-approval commitments. We work inside real operating constraints: protocol amendments, enrollment pressure, vendor handoffs, and inspection timelines that do not wait for perfect conditions. The first job is usually to make ownership clear so sponsor, CRO, and site responsibilities do not collide when something goes wrong.

Typical engagement starts with clarity on study phase, indication, and oversight model. We help define monitoring strategy, safety reporting workflows, and TMF ownership before first patient in, then revisit those choices when the protocol changes. Amendment impact is reviewed against eligibility, visit schedules, EDC fields, and investigational product labeling rather than treated as a paperwork exercise. When enrollment lags, we look at site-level barriers and competing studies instead of only adding more sites to the list.

Our consultants bring hands-on experience with protocol review, site activation planning, risk-based monitoring, and clinical quality oversight. We can sit with your clinical operations lead, embed with a functional team, or advise on selective gaps such as SAE reconciliation, CAPA follow-through after an audit finding, or inspection prep for FDA or EMA clinical questions. Work is scoped to the study and the decisions you need to make next, including how vendor KPIs and meeting cadence will surface issues early enough to act.

Across phases, pharmaceutical trials fail more often from weak operational control than from a missing slide deck. We keep attention on source verification quality, protocol deviation trends, query aging, and whether the CSR narrative will match what the TMF and clinical database show. That focus helps teams reach database lock and submission interactions with fewer last-minute surprises.

Pharmaceutical clinical support commonly covers

• Protocol and amendment feasibility reviews
• Site selection criteria and activation readiness
• Monitoring plans and visit report quality checks
• Safety reporting and SAE reconciliation support
• TMF completeness tracking against study milestones
• Inspection preparation for FDA or EMA clinical reviews
• Vendor oversight for CRO and lab partners

If you are building a pharmaceutical trial program or stabilizing an active study, we can assess where operations, quality, and documentation are out of sync and set a practical path forward without inventing work your team does not need.